Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2014-10-01 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
PR INITIATION OF A PHASE I CLINICAL TRIAL OF LIRILUMAB
Regulatory Filings Classification · 96% confidence The document is a press release dated October 1, 2014, announcing the initiation of a Phase I clinical trial for a drug combination (lirilumab with elotuzumab) in multiple myeloma patients. It details the study design, purpose, and provides background information on the drug and the company (Innate Pharma). This type of announcement, focusing on clinical trial progress and scientific updates, is characteristic of an Investor Presentation (IP) or a general press release related to R&D activities. Since it is a formal announcement detailing scientific progress and strategic alliances, and not a standard regulatory filing like 10-K or a simple earnings release, 'Investor Presentation' (IP) is the most fitting category for detailed scientific/pipeline updates presented to investors, although it functions as a press release. Given the options, 'IP' captures the nature of the detailed scientific/pipeline update better than the generic 'RNS'. However, since it is primarily a press release announcing a clinical trial update, and not a structured presentation deck, 'RNS' (Regulatory Filings/General Announcement) is often used for such non-standard, time-sensitive corporate news that doesn't fit other specific categories like ER or CAP. Given the detailed nature of the scientific update, I will lean towards 'IP' as it serves an investor information purpose, but acknowledge it could be RNS. Comparing it to the definitions, it is not a formal report (10-K, IR), nor a management change (MANG), nor a financing event (CAP). It is a specific update on R&D, which often falls under Investor Presentation materials. I will classify it as IP.
2014-10-01 English
PR INITIATION OF A PHASE I CLINICAL TRIAL OF LIRILUMAB
Regulatory Filings Classification · 96% confidence The document is a press release dated October 1, 2014, announcing the initiation of a Phase I clinical trial for a drug combination (lirilumab with elotuzumab) in multiple myeloma patients. It details the study design, purpose, and provides background information on the drug and the company (Innate Pharma). This type of announcement, focusing on clinical trial progress and scientific updates, is characteristic of an Investor Presentation (IP) or a general press release related to R&D activities. Since it is a formal announcement detailing scientific progress and strategic alliances, and not a standard regulatory filing like 10-K or a simple earnings release, 'Investor Presentation' (IP) is the most fitting category for detailed scientific/pipeline updates presented to investors, although it functions as a press release. Given the options, 'IP' captures the nature of the detailed scientific/pipeline update better than the generic 'RNS'. However, since it is primarily a press release announcing a clinical trial update, and not a structured presentation deck, 'RNS' (Regulatory Filings/General Announcement) is often used for such non-standard, time-sensitive corporate news that doesn't fit other specific categories like ER or CAP. Given the detailed nature of the scientific update, I will lean towards 'IP' as it serves an investor information purpose, but acknowledge it could be RNS. Comparing it to the definitions, it is not a formal report (10-K, IR), nor a management change (MANG), nor a financing event (CAP). It is a specific update on R&D, which often falls under Investor Presentation materials. I will classify it as IP.
2014-10-01 English
CP DEMARRAGE D’UN NOUVEL ESSAI DE PHASE I
Regulatory Filings Classification · 95% confidence The document is a press release dated October 1, 2014, announcing the initiation and publication of a new Phase I clinical trial for Lirilumab in combination with Elotuzumab for multiple myeloma. It details the trial objectives, design, and provides background information on the drug and the company (Innate Pharma). This type of announcement, which communicates key operational and clinical development news to the market, is characteristic of an Earnings Release (ER) if it were summarizing financial results, or more generally, a Regulatory Filing (RNS) if it's a broad announcement. However, given the specific focus on clinical trial updates and partnership activities, it is not a standard 10-K, IR, or ER. It is a formal announcement of a significant corporate/clinical event. Since there is no specific category for 'Clinical Trial Announcement' and it is not a transcript (CT), a presentation (IP), or a management discussion (MDA), the most appropriate general category for a formal, non-financial results announcement that is not a specific regulatory form is Regulatory Filings (RNS). The document length (6598 chars) is substantial enough that it is the primary content, not just a brief notice of publication (which would be RPA).
2014-10-01 French
IPH_EffiKIR third DSMB
Regulatory Filings Classification · 95% confidence The document is a press release dated September 25, 2014, announcing that the Data and Safety Monitoring Board (DSMB) for the EffiKIR trial recommended continuation as planned. It details clinical trial progress, scientific rationale, and corporate information. This type of announcement, focusing on operational updates, clinical trial milestones, and general company news, is typically classified as a Regulatory Filing (RNS) if it doesn't fit a more specific category like Earnings Release (ER) or Capital Update (CAP). Since it is not a formal financial report (like 10-K or IR) nor a specific announcement about dividends, management changes, or voting results, the general regulatory announcement category (RNS) is the most appropriate fit, as it serves as a broad disclosure to the market.
2014-09-25 English
IPH_Troisième DSMB EffiKIR
Regulatory Filings Classification · 89% confidence The document is a press release dated September 25, 2014, from Innate Pharma SA. It announces that the Data and Safety Monitoring Board (DSMB) has recommended the continuation of the EffiKIR clinical trial as planned. The text details the trial's status (recruitment complete, primary endpoint expected end of 2015), describes the trial (Phase II, testing lirilumab for AML), and provides background on the drug and the company. This type of announcement, detailing progress or key milestones in ongoing clinical trials, is characteristic of an Earnings Release (ER) if it were tied to financial results, or more generally, a corporate update. Since it is a specific announcement about a clinical trial milestone and not a full financial report (10-K, IR), a management discussion (MDA), or a formal regulatory filing like a DVA or LTR, it fits best as an Earnings Release (ER) if we interpret 'Earnings Release' broadly to include significant operational updates that drive investor interest, or as a general Regulatory Filing (RNS) if ER is strictly for financial results. Given the context of clinical trial updates being crucial operational news often released alongside or instead of quarterly results, ER is a strong candidate, but RNS is the safest fallback for non-standard operational news. However, many companies issue press releases for clinical trial updates that function similarly to earnings highlights. Since this is a specific, time-sensitive operational update, and not a comprehensive report, it is most closely aligned with the function of an Earnings Release (ER) which communicates key period performance/milestones, or potentially a Regulatory Filing (RNS). Given the content is a specific, positive operational update (DSMB recommendation), I will classify it as an Earnings Release (ER) as these often include operational highlights, though RNS is also plausible. Given the lack of explicit financial figures, RNS is the most neutral fit for a non-standard corporate announcement, but ER often covers operational milestones. I will lean towards ER as it is a significant, time-bound operational update.
2014-09-25 French
Interim Financial Report
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim Financial Report June 30, 2014'. It contains comprehensive consolidated financial statements, management discussion and analysis (MDA), and a limited review report by statutory auditors for a six-month period. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2014
2014-09-19 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.